ELICIO THERAPEUTICS INC
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Elicio Therapeutics stock, expecting it to rise to $10 per share.
Financial Health
Elicio Therapeutics is producing strong cash flow, indicating good financial stability and operational efficiency.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ELTX
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Novel vaccine platforms
Elicio’s technology aims to stimulate anti-tumour immunity; progress in trials could unlock value, though clinical outcomes are uncertain.
Catalysts to watch
Key near-term catalysts include trial readouts, partnerships and regulatory steps, which can move the stock significantly but also carry downside.
Funding and partnerships
Small market cap firms often need additional capital or collaborations to commercialise therapies; these deals can be value-driving yet dilutive.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
